Doctors tested a common drug on Covid. Amazing results

The study analyzed the data of approximately 500 patients in the hospital with Covid-19 across six countries. Patients who inhaled the heparin most likely needed ventilation and had a much lower risk than death compared to those who received standard care.

Hebarin, a traditional injection drug for blood clots, was tested in this study in the form of inhale, and targeting the lungs directly. In addition to acting as an anticoagulant loss, heparin has anti -inflammatory and virus properties. The results of the previous research showed that breathing and oxygen levels improved in the patients of Covid-19 after they inhaled a course of heparin.

Researchers believe that the drug can also be useful in combating other serious respiratory infections such as pneumonia.

“The inhaled heparin is hostile to viruses and anti -inflammatory, and there are still any patients.

While the results highlight the inhaled heparin capabilities, further development is needed before the treatment is routinely adopted. Researchers believe that the drug can also be useful in combating other serious respiratory infections such as pneumonia, which can be caused by a group of viruses and bacteria.

According to Professor Van Harin, the drug will also be useful for those with an immune system, such as cancer patients, when they suffer from respiratory infection.

Professor Frank Van Harin, the main author, Anu and director of the intensive care unit at St. George Hospital in Sydney, said: “It does not matter which kind of respiratory infection with which the patient deals, and we are drugs – when inhaled – it will prevent him from injuring the patient and attaching them to destroy the lungs. Low income countries “

Researchers are now developing an improved formula for heparin, specially designed to be given by inhalation.

The research has been published in Eclinicalmedicine At the same time it was presented at the International Conference at the European respiratory association (ERS) in Amsterdam on Sunday, September 28, which is the pioneering annual community of respiratory research.